EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)

Howard S Hochster iD, Paul Catalano, Michelle Weitz, Edith P Mitchell, Deirdre Cohen, Peter J O'Dwyer, Bryan A Faller, Jeremy S Kortmansky, Mark H O'Hara, Sheetal M Kricher, Jill Lacy, Heinz-Josef Lenz und 2 weitere

JNCI: Journal of the National Cancer Institute · 2024

DOI: 10.1093/jnci/djae114 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Howard S Hochster und 13 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Cancer Institute, New Brunswick, NJ, USA. Hauptthemen laut MEDLINE: Ramucirumab, Irinotecan, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS, ECOG-ACRIN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Early studies showed promise of combined anti-epidermal growth factor receptor (EGFR) plus anti–vascular endothelial growth factor (VEGF) antibodies for advanced colorectal cancer (CRC), yet this was later rejected as toxic and ineffective in studies not selected for RAS status. We studied advanced KRAS wild-type CRC, as second-line treatment, using irinotecan-cetuximab with or without the anti-VEGF receptor antibody ramucirumab.

Methods

Patients with 1 prior regimen including fluoropyrimidine, oxaliplatin, and bevacizumab, with KRAS wild-type tumors were stratified by Eastern Cooperative Oncology Group Performance Score, time since last chemotherapy, and progression on oxaliplatin to irinotecan-cetuximab (IC) (180 mg/m2 and 500 mg/m2 every 2 weeks) vs modified ICR (irinotecan-cetuximab with ramucirumab 150 mg/m2 and 400 mg/m2 plus 6 mg/kg, respectively). A total of 102 patients were compared for progression-free survival (PFS) as primary endpoint (85% power for 70% improvement in median PFS from 4.5 to 7.65 months).

Results

Of the 102 enrolled, 44 treated with irinotecan-cetuximab and 45 with modified ramucirumab were evaluable. Median PFS was 6.0 months vs 9.2 months, respectively (hazard ratio = 0.75, P = .07; statistically significant by study design for P < .128). Response rate was 23% vs 36% (P = .27), and disease-control rate was 52% vs 73% (P = .05). Grade 3 or higher toxicity was equivalent. Overall survival was not significantly different at approximately 19 months.

Conclusion

Previous phase 3 trials without RAS genotyping rejected combining anti-epidermal growth factor receptor and anti-VEGF drugs. In this randomized multicenter phase 2 study for KRAS wild-type CRC (all previously bevacizumab treated), the addition of ramucirumab to irinotecan and cetuximab improved PFS and disease control rate, showing the combination is feasible and effective. Further, phase 3 trials with appropriate patient-selection are required. (NCT01079780)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RamucirumabIrinotecanColorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedCetuximabErbB ReceptorsHumansFemaleMaleAgedMiddle AgedAdultVascular Endothelial Growth Factor AAged, 80 and overProgression-Free Survival

Substanzen

RamucirumabIrinotecanAntibodies, Monoclonal, HumanizedCetuximabErbB ReceptorsVascular Endothelial Growth Factor AEGFR protein, human

Autor:innen und Institutionen

  • Rutgers Cancer Institute, New Brunswick, NJ, USA.
  • ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
  • Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Mt Sinai Hospital, New York, NY, USA.
  • University of Pennsylvania, Philadelphia, PA, USA.
  • Missouri Baptist Medical Center Heartland NCORP, St Louis, MO, USA.

ORCID-Profile: Howard S Hochster

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • ECOG-ACRIN
  • Cancer Research Group
  • NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Hochster, H. S., Catalano, P., Weitz, M., Mitchell, E. P., Cohen, D., O'Dwyer, P. J., Faller, B. A., Kortmansky, J. S., O'Hara, M. H., Kricher, S. M., Lacy, J., Lenz, H. J., Verma, U., & Benson, A. B. (2024). Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208). JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae114

Vancouver

Hochster HS, Catalano P, Weitz M, Mitchell EP, Cohen D, O'Dwyer PJ, et al. Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208). JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae114

BibTeX
@article{Hochster2024,
  author = {Hochster, Howard S and Catalano, Paul and Weitz, Michelle and Mitchell, Edith P and Cohen, Deirdre and O'Dwyer, Peter J and Faller, Bryan A and Kortmansky, Jeremy S and O'Hara, Mark H and Kricher, Sheetal M and Lacy, Jill and Lenz, Heinz-Josef and Verma, Udit and Benson, Al B},
  title = {Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  doi = {10.1093/jnci/djae114}
}
Kostenlos starten →